Literature DB >> 14690607

Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.

K Farid Ahmad1, Ari Melnick, Stuart Lax, Denis Bouchard, Jun Liu, Chih-Li Kiang, Sebastian Mayer, Shinichiro Takahashi, Jonathan D Licht, Gilbert G Privé.   

Abstract

BCL6 encodes a transcription factor that represses genes necessary for the terminal differentiation of lymphocytes within germinal centers, and the misregulated expression of this factor is strongly implicated in several types of B cell lymphoma. The homodimeric BTB domain of BCL6 (also known as the POZ domain) is required for the repression activity of the protein and interacts directly with the SMRT and N-CoR corepressors that are found within large multiprotein histone deacetylase-containing complexes. We have identified a 17 residue fragment from SMRT that binds to the BCL6 BTB domain, and determined the crystal structure of the complex to 2.2 A. Two SMRT fragments bind symmetrically to the BCL6 BTB homodimer and, in combination with biochemical and in vivo data, the structure provides insight into the basis of transcriptional repression by this critical B cell lymphoma protein.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14690607     DOI: 10.1016/s1097-2765(03)00454-4

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  102 in total

Review 1.  POK/ZBTB proteins: an emerging family of proteins that regulate lymphoid development and function.

Authors:  Sung-Uk Lee; Takahiro Maeda
Journal:  Immunol Rev       Date:  2012-05       Impact factor: 12.988

2.  Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein.

Authors:  Fabien Guidez; Louise Howell; Mark Isalan; Marek Cebrat; Rhoda M Alani; Sarah Ivins; Itsaso Hormaeche; Melanie J McConnell; Sarah Pierce; Philip A Cole; Jonathan Licht; Arthur Zelent
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

3.  Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.

Authors:  Alexandru F Ghetu; Connie M Corcoran; Leandro Cerchietti; Vivian J Bardwell; Ari Melnick; Gilbert G Privé
Journal:  Mol Cell       Date:  2008-02-15       Impact factor: 17.970

4.  Structure of the wild-type human BCL6 POZ domain.

Authors:  Mark A Stead; Gareth O Rosbrook; Jonathan M Hadden; Chi H Trinh; Stephen B Carr; Stephanie C Wright
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2008-11-28

5.  Structure of the human Nac1 POZ domain.

Authors:  Mark A Stead; Stephen B Carr; Stephanie C Wright
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-04-24

Review 6.  B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.

Authors:  Weimin Ci; Jose M Polo; Ari Melnick
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

Review 7.  HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors.

Authors:  Capucine Fleuriel; Majid Touka; Gaylor Boulay; Cateline Guérardel; Brian R Rood; Dominique Leprince
Journal:  Int J Biochem Cell Biol       Date:  2008-08-03       Impact factor: 5.085

8.  BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy.

Authors:  Leandro C Cerchietti; Katerina Hatzi; Eloisi Caldas-Lopes; Shao Ning Yang; Maria E Figueroa; Ryan D Morin; Martin Hirst; Lourdes Mendez; Rita Shaknovich; Philip A Cole; Kapil Bhalla; Randy D Gascoyne; Marco Marra; Gabriela Chiosis; Ari Melnick
Journal:  J Clin Invest       Date:  2010-11-01       Impact factor: 14.808

9.  Sequential transcription factor targeting for diffuse large B-cell lymphomas.

Authors:  Leandro C Cerchietti; Jose M Polo; Gustavo F Da Silva; Pedro Farinha; Rita Shaknovich; Randy D Gascoyne; Steven F Dowdy; Ari Melnick
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

Review 10.  Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas.

Authors:  Samir Parekh; Gilbert Privé; Ari Melnick
Journal:  Leuk Lymphoma       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.